Fairvalue-Calculator Fairvalue-Calculator
EN DE

MaxCyte, Inc (MXCT) Fair Value & Analysis

Healthcare · US · Market cap $130M

Price$1.19
Fair Value$0.8200
Upside-31.1%
Quality95/100
Evidence: Low Range $0.5400 – $1.02

Fair value as of: Jun 25, 2026

Analysis

MaxCyte, Inc (MXCT) currently trades at $1.19, while our model-based Fair Value estimate is $0.8200 — implying the stock looks roughly 31.1% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCy…

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABT) -95% Stryker Corporation (S1YK34) -45% Medtronic plc (MDT) -27% Boston Scientific Corporation (B1SX34) -11% Edwards Lifesciences Corporation (EW) -52% Siemens Healthineers AG (SEMHF) +11%

Frequently asked questions

Is MaxCyte, Inc (MXCT) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $0.8200 versus a price of $1.19 — about −31% (overvalued). Model-based estimate, not financial advice.
What is the fair value of MXCT?
Our 21-model fair value for MaxCyte, Inc is $0.8200 (as of Jun 25, 2026), built from audited fundamentals. The current price is $1.19.
What is the quality score of MXCT?
MaxCyte, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.